List of Metrogel drug patents

Metrogel is owned by Galderma Labs Lp.

Metrogel contains Metronidazole.

Metrogel has a total of 2 drug patents out of which 2 drug patents have expired.

Expired drug patents of Metrogel are:

  • US7348317
  • US6881726

Metrogel was authorised for market use on 30 June, 2005.

Metrogel is available in gel;topical dosage forms.

Metrogel can be used as once a day topical treatment of the inflammatory lesions of rosacea.

The generics of Metrogel are possible to be released after 21 February, 2022.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7348317 GALDERMA LABS LP Aqueous compositions containing metronidazole
Feb, 2022

(1 year, 1 month ago)

US6881726 GALDERMA LABS LP Aqueous compositions containing metronidazole
Feb, 2022

(1 year, 1 month ago)

Drugs and Companies using METRONIDAZOLE ingredient

Market Authorisation Date: 30 June, 2005

Treatment: Once a day topical treatment of the inflammatory lesions of rosacea

Dosage: GEL;TOPICAL

How can I launch a generic of METROGEL before it's patent expiration?
More Information on Dosage

METROGEL family patents

5

United States

3

European Union

2

Russia

1

South Africa

1

Denmark

1

Austria

1

Mexico

1

Australia

1

Hong Kong

1

Germany

1

Argentina

1

Brazil

1

Portugal

1

Cyprus

1

Spain

1

Korea, Republic of

1

China

1

Japan

1

Canada

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in